Can ENTRESTO use pay-for-performance schemes and patient monitoring services to justify its anticipated budget impact in the U.S.?

Novartis’ recently approved ENTRESTO impressed regulators with stellar clinical outcomes, including a 20% reduction in the risk of cardiovascular death and hospitalization and a 16% improvement in overall survival compared to the standard-of-care ACE inhibitor therapy enalapril. ENTRESTO is expected to change the management of heart failure with reduced ejection…

Big Partnerships for Big Data in Healthcare

Big data has made a serious impression in healthcare. A slew of recent announcements have recently come from some of the biggest healthcare organisations, many of them involving collaborations with major players in technology: IBM’s Watson is poised to partner with Apple, Johnson & Johnson, and Medtronic on a number…

Page 1 of 212